Wells Fargo lowered the firm’s price target on Editas Medicine (EDIT) to $7 from $9 and keeps an Overweight rating on the shares. The firm continues to see Editas’ focus on in vivo HSPC editing as a more effective use of its expertise and resources to create value. Wells looks forward to the next in vivo pipeline update in Q1 2025 as well as updates on reni-cel BD activity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine price target lowered to $5 from $7 at Barclays
- Editas Medicine Reports Q3 2024 Results and Developments
- Editas Medicine price target lowered to $5 from $8 at RBC Capital
- Raymond James downgrades Editas on extended development timelines
- Editas Medicine downgraded to Market Perform from Outperform at Raymond James